53 patents currently held
38 more in force are now held by other companies
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
The next term ends in Aug 2027. from the record
Of the 38 now held by other companies, 20 name Daiichi Sankyo Inc. as their current owner, and 18 more name another party. Each row says which.
Free plan: 3 watched companies. Pro: unlimited.
Alerts on its grants, lapses and transfers.
22
Ending by 2030
Aug 2027
Next term end
40
Patent families
When these terms end
Held patents by the year their term ends
notable patents
fee due within 90 days
all others
Updated Nov 16, 2026 · includes USPTO assignment & status data published Nov 16, 2026 and grant & fee data published Nov 10, 2026 (weekly) · how we know
Notable: the highest-ranked patents in this portfolio by citations and family size. Fee due within 90 days: a maintenance fee is due within 90 days of when this page was computed and not yet paid.
Notable patents
Ranked by citations and family size, against patents of the same kind granted the same year. How we rank
Notable
Ends Jun 2029 · High confidence
Also notable
Ends Feb 2032 · High confidence
Also notable
Ends Jul 2028 · High confidence
Compounds and Methods for Kinase Modulation, and Indications Therefor
US 7,863,288
The most cited patent in this portfolio, cited by 166 later US patents, top 5% of utility patents granted in 2011 in our data. Protection runs to 2029.
Compounds and Methods for Kinase Modulation, and Indications Therefor
US 11,337,976
Cited by 40 later US patents, top 5% of utility patents granted in 2022 in our data. Protection runs to 2032.
Compounds and Methods for Kinase Modulation, and Indications Therefor
US 9,469,640
Cited by 51 later US patents, top 10% of utility patents granted in 2016 in our data, and renewed at every maintenance window due so far. Protection runs to 2028.
Formerly held, still cited
Notable
Ends Mar 2034 · Medium confidence
Cited by 71 later US patents, top 5% of utility patents granted in 2017 in our data, and renewed at every maintenance window due so far. Protection runs to 2034. A terminal disclaimer caps this term to an earlier patent's.
now held by Opna Bio S.A.
Fee deadlines
Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
- 1 fee due Nov 28, 2026The maintenance fee for Compounds and Methods for Kinase Modulation, and Indications Therefor (US 10,301,280) comes due Nov 28, 2026. Unpaid by May 28, 2027, it lapses early.
- 1 fee due Dec 11, 2026The maintenance fee for Solid Forms of a Compound for Modulating Kinases (US 10,316,032) comes due Dec 11, 2026. Unpaid by Jun 11, 2027, it lapses early.
- 2 fees due Feb 4 to 28, 2027 · next Feb 4
- 1 fee due Mar 24, 2027The maintenance fee for Compounds for Kinase Modulation, and Indications Therefor (US 10,421,761) comes due Mar 24, 2027. Unpaid by Sep 24, 2027, it lapses early.
- 3 fees due Apr 1 to 6, 2027 · next Apr 1
- 1 fee due Jun 17, 2027The maintenance fee for Compounds and Methods for Ido and Tdo Modulation, and Indications Therefor (US 10,508,085) comes due Jun 17, 2027. Unpaid by Dec 17, 2027, it lapses early.
- 1 fee due Aug 16, 2027The maintenance fee for Compounds and Methods for Kinase Modulation, and Indications Therefor (US 9,260,437) comes due Aug 16, 2027. Unpaid by Feb 16, 2028, it lapses early.
Recent changes
- 1 term has ended since Aug 18, 2026
What they patent
The 5 largest of its 40 families, grouped by real patent family and labeled by the earliest filing in each. No technology classification is inferred from titles.
| Compounds and Methods for Kinase Modulation, and Indications Therefor (2013) | 3 in force | to Feb 2032 |
| Compounds and Methods for Kinase Modulation, and Indications Therefor (2009) | 3 in force | to Nov 2029 |
| Compounds and Methods for Kinase Modulation, and Indications Therefor (2016) | 3 in force | to Jul 2028 |
| Synthesis of Heterocyclic Compounds (2021) | 2 in force | to May 2041 |
| Synthesis of Heterocyclic Compounds (2016) | 2 in force | to May 2036 |
Patents held now
Soonest term end first.
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 8,415,469 | Compounds and Methods for Kinase Modulation, and Indications Therefor In force · High confidence | In force | High confidence | |
| US 7,585,859 | PDE4B Inhibitors and Uses Therefor In force · High confidence | In force | High confidence | |
| US 7,605,168 | PDE4B Inhibitors In force · High confidence | In force | High confidence | |
| US 9,469,640 | Compounds and Methods for Kinase Modulation, and Indications Therefor In force · High confidence | In force | High confidence | |
| US 9,844,539 | Compounds and Methods for Kinase Modulation, and Indications Therefor In force · High confidence | In force | High confidence | |
| US 10,426,760 | Compounds and Methods for Kinase Modulation, and Indications Therefor In force · High confidence | In force | High confidence | |
| US 7,846,941 | Compounds Modulating C-Kit and C-Fms Activity and Uses Therefor In force · High confidence | In force | High confidence | |
| US 7,863,289 | Compounds and Methods for Kinase Modulation, and Indications Therefor In force · Medium confidence | In force | Medium confidence | |
| US 9,260,437 | Compounds and Methods for Kinase Modulation, and Indications Therefor In force · High confidence | In force | High confidence | |
| US 8,110,576 | Substituted PYRROLO[2,3B]PYRAZINES and Methods for Treatment of Raf Protein Kinase-Mediated Indications In force · Medium confidence | In force | Medium confidence |
Also on record, not counted in the 53: 38 patents in force now held by others · 15 patents ended · 3 applications pending · 58 applications abandoned. List them
Sources and methods
Compiled from USPTO application file histories, grants and recorded assignments, with the company's own names reviewed by hand. How this record was built
Portfolio grouped automatically from ownership conveyances to the names matched to this company, usually every name that begins with its own, so it counts patents an affiliate holds; each list row names the holder of record. Security interests are excluded and ambiguous records are not reviewed by hand.
Fee due within 90 days marks a patent with a maintenance fee due within 90 days of the date this page was computed and not yet recorded paid, so it can end earlier than the bar shows. A fee left unpaid ends the patent at the close of the six month grace period that follows its due date, not on the due date itself. It is not a prediction that the fee will be missed.
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.